Dr. Matous, a Member Physician at the Colorado Blood Cancer Institute in Denver and part of the Sarah Cannon Research Institute, shares results from the phase Ib MonumenTAL-2 study at the 65th American Society of Hematology Annual Meeting & Exposition.
The investigators studied the combination of talquetamab plus pomalidomide in patients with relapsed or refractory multiple myeloma.
“The results of the study, I think, are very impressive and in my mind demonstrate the most potent combination of pomalidomide with another agent that we’ve ever seen in clinical medicine before,” Dr. Matous said.